CTVA Earnings

CTVA reported its earnings on 2026-02-03, showcasing a revenue of 3.91B against an estimate of 4.23B, resulting in a -7.57% surprise. The EPS was 0.22, surpassing the expected 0.21 by 4.76%. The stock experienced a 0.11% price change on the earnings day and a -1.89% change over the next five days, reflecting market reactions to the results.

Following CTVA's earnings announcement on 2026-02-03, the stock price moved by 0.11% on the day of the release. Over the subsequent five days, it saw a -1.89% change. Historically, CTVA's stock price tends to shift by an average of -1.09% in the 10 days leading up to earnings and 2.16% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate CTVA's annual revenue to reach 4.64B, while the EPS is projected at 1.18. These estimates reflect recent revisions, with revenue estimates revised upward by 0.01% and EPS estimates revised downward by -0.03% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CTVA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised upward by 0.01%, while EPS estimates moved revised downward by -0.03%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CTVA's stock price typically moves by -1.09% in the 10 days before its earnings and 2.16% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 1.18 and revenue of 4.64B.

Corteva's earnings call indicates strong financial performance with 14% EBITDA growth and improved margins. The strategic separation into two companies and new product launches are positive indicators. The Q&A highlights promising developments like the Bayer agreement and gene editing prospects in Europe. Despite some currency headwinds and SG&A increases, the overall sentiment remains positive due to strong market position, growth in key markets, and optimistic financial guidance, warranting a positive stock price prediction.